GlycoMantra has been awarded a two-year SBIR Phase 2 grant ($3.7 M) from the NIDDK…
June 12, 2018
GlycoMantra received a CDMRP grant from the DOD.
GlycoMantra was awarded a CDMRP grant to develop personalized cellular immunotherapy for kidney cancer.
